Drug Detail:Etopophos (Etoposide phosphate [ e-toe-poe-side-fos-fate ])
Generic Name: etoposide phosphate 100mg
Dosage Form: injection, powder, lyophilized, for solution
Drug Class: Mitotic inhibitors
Drug Detail:Etopophos (Etoposide phosphate [ e-toe-poe-side-fos-fate ])
Generic Name: etoposide phosphate 100mg
Dosage Form: injection, powder, lyophilized, for solution
Drug Class: Mitotic inhibitors
The recommended dose of ETOPOPHOS is:
The recommended dose of ETOPOPHOS is:
• 35 mg/m2 per day administered intravenously over 5 minutes to 3.5 hours for 4 days, or
• 50 mg/m2 per day administered intravenously over 5 minutes to 3.5 hours for 5 days.
In patients with a creatinine clearance (CLcr) 15-50 mL/min, administer 75% of the recommended dose.
Data are not available in patients with CLcr less than 15 mL/min. Consider further dose reduction in these patients.
Preparation
Vial Strength | Volume of Diluent | Final Concentration |
100 mg | 5 mL | 20 mg/mL |
10 mL | 10 mg/mL |
Storage
After reconstitution, store under the following conditions:
Reconstituted ETOPOPHOS solutions further diluted as directed can be stored under refrigeration 2° to 8°C (36° to 46°F) or at room temperature 20° to 25°C (68° to 77°F) for 24 hours.
Administration
DO NOT GIVE ETOPOPHOS BY BOLUS INTRAVENOUS INJECTION. ETOPOPHOS solutions may be administered at infusion rates up to 3.5 hours. Extravasation of ETOPOPHOS may result in swelling, pain, cellulitis, and necrosis including skin necrosis.
ETOPOPHOS is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 To minimize the risk of dermal exposure, use of gloves is recommended. If dermal contact occurs, immediately and thoroughly wash areas of skin contact with soap and water and flush mucosa with water.